Dr. William Sharfman, M.D.
Medical Oncology (Medical Oncology Physician)
10755 Falls Rd
Lutherville, MD 21093
Who else practices at this address →
Baltimore County includes dental (23% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Toledo College of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 558
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of Toledo College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MD license D38409
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Johns Hopkins Hospital, the Baltimore, MD
- Wellspan York Hospital York, PA
Medical groups
- Johns Hopkins University (2,909 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 558
- Services billed
- 326,675
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 83,820 | 37 |
| Injection, cemiplimab-rwlc, 1 mg | 45,500 | 17 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 26,820 | 13 |
| Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | 23,680 | 24 |
| Injection, pembrolizumab, 1 mg | 23,400 | 22 |
| Injection, fosaprepitant, 1 mg | 6,750 | 14 |
| Injection, ipilimumab, 1 mg | 6,150 | 12 |
| Injection, ondansetron hydrochloride, per 1 mg | 2,528 | 30 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,298 | 22 |
| Administration of chemotherapy into vein, 1 hour or less | 862 | 118 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Lutherville, MD | 126 |
| Pantoprazole Sodium Other prescribers in Lutherville, MD | 95 |
| Prednisone Other prescribers in Lutherville, MD | 88 |
| Oxycodone Hcl Other prescribers in Lutherville, MD | 66 |
| Hydrocortisone Other prescribers in Lutherville, MD | 46 |
| Mektovi (binimetinib) | 32 |
| Braftovi (encorafenib) | 31 |
| Lorazepam Other prescribers in Lutherville, MD | 22 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Lutherville, MD | 21 |
| Tramadol Hcl Other prescribers in Lutherville, MD | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $20.86 in total to this clinician.
| Gilead Sciences, Inc. | $20.86 |
|---|
| Food and Beverage | $20.86 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 5 companies. The companies reported $871,699 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Sta…
Merck Sharp & Dohme LLC - A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition
AstraZeneca UK Limited - A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02A
Merck Sharp & Dohme LLC - Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716
Merck Sharp & Dohme LLC - A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
E.r. Squibb & Sons, L.l.c. - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody…
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
E.r. Squibb & Sons, L.l.c. - IOV-EAP-402
Iovance Biotherapeutics, Inc. - Study name not reported
Organon Llc - A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02B
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.